Press Release

by Rachel on June 1, 2010

Press Release
Advaxis Inc. Posted on:28 May 10 Advaxis, Inc . , (OTCBB: ADXS) , the live, attenuated Listeria monocytogenes ( Lm ) biotechnology company, has dosed the first patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.

Read more on PharmiWeb

Leave a Comment

Previous post:

Next post: